JP2021073194A5 - - Google Patents

Download PDF

Info

Publication number
JP2021073194A5
JP2021073194A5 JP2020218615A JP2020218615A JP2021073194A5 JP 2021073194 A5 JP2021073194 A5 JP 2021073194A5 JP 2020218615 A JP2020218615 A JP 2020218615A JP 2020218615 A JP2020218615 A JP 2020218615A JP 2021073194 A5 JP2021073194 A5 JP 2021073194A5
Authority
JP
Japan
Prior art keywords
salt
composition
composition according
weight
hetre
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020218615A
Other languages
English (en)
Other versions
JP2021073194A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021073194A publication Critical patent/JP2021073194A/ja
Publication of JP2021073194A5 publication Critical patent/JP2021073194A5/ja
Pending legal-status Critical Current

Links

Claims (6)

  1. 15−ヒドロキシ−8(Z),11(Z),13(E)−エイコサトリエン酸(15−HETrE)の塩を含む組成物であって、15−HETrEの塩形態を、該組成物の全重量の約0.1重量%〜約20重量%の量で含む、前記組成物。
  2. 前記塩が、リジン塩、ナトリウム塩、オルニチン塩、ピペラジン塩、またはメグルミン塩である、請求項1に記載の組成物。
  3. 賦形剤をさらに含む、請求項1に記載の組成物。
  4. 界面活性剤、保存剤、香味剤、共溶剤、粘度助剤、懸濁助剤、及び/または親油相のうちの1つ以上をさらに含む、請求項1に記載の組成物。
  5. 局所投与用に製剤化される、請求項1に記載の組成物。
  6. クリーム、ゲル、エマルション、油、またはローションとして製剤化される、請求項5に記載の組成物。
JP2020218615A 2013-11-15 2020-12-28 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩 Pending JP2021073194A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904600P 2013-11-15 2013-11-15
US61/904,600 2013-11-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019212877A Division JP6818851B2 (ja) 2013-11-15 2019-11-26 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩

Publications (2)

Publication Number Publication Date
JP2021073194A JP2021073194A (ja) 2021-05-13
JP2021073194A5 true JP2021073194A5 (ja) 2021-11-25

Family

ID=52669635

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016530882A Pending JP2016538288A (ja) 2013-11-15 2014-11-17 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
JP2019212877A Expired - Fee Related JP6818851B2 (ja) 2013-11-15 2019-11-26 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
JP2020218615A Pending JP2021073194A (ja) 2013-11-15 2020-12-28 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2016530882A Pending JP2016538288A (ja) 2013-11-15 2014-11-17 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
JP2019212877A Expired - Fee Related JP6818851B2 (ja) 2013-11-15 2019-11-26 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩

Country Status (6)

Country Link
US (3) US10017453B2 (ja)
EP (3) EP3068757B1 (ja)
JP (3) JP2016538288A (ja)
CN (2) CN109232278A (ja)
ES (1) ES2727387T3 (ja)
WO (1) WO2015071766A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016370626B2 (en) 2015-12-18 2020-08-20 Afimmune Limited Compositions comprising 15-HEPE and methods of using the same
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
WO2022090482A1 (en) 2020-10-30 2022-05-05 Ds Biopharma Limited Pharmaceutical compositions comprising 15-hetre and methods of use thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3055923A (en) * 1960-03-25 1962-09-25 Baxter Laboratories Inc Fatty acid salts
IE47777B1 (en) 1978-01-23 1984-06-13 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
US5352700A (en) 1988-01-14 1994-10-04 Anders Frithz Use of essential fatty acids for the preparation of a drug for the treatment of infantile seborrheic eczema
GB9111900D0 (en) 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
JPH05186342A (ja) 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
SK66198A3 (en) * 1996-09-20 1999-09-10 Atherogenics Inc Diagnostics for and mediators of inflammatory disorders
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
US6359158B1 (en) * 1998-05-15 2002-03-19 University Of Vermont And State Agricultural College Methods and products related to 16-HETE analogs
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
US6429227B1 (en) * 1999-11-09 2002-08-06 Alcon Universal Ltd. Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders
AU3846801A (en) 2000-02-16 2001-08-27 Brigham & Womens Hospital Aspirin-triggered lipid mediators
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
DE10121252A1 (de) 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
WO2004072013A1 (ja) * 2003-02-14 2004-08-26 Taisho Pharmaceutical Co.,Ltd. ヒドロキシエイコサジエン酸化合物
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
WO2005063231A2 (en) 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
WO2005102309A2 (en) 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
CA2599112C (en) 2005-02-14 2013-10-22 Suntory Limited Composition comprising dihomo-.gamma.-linolenic acid (dgla) as the active ingredient
TW200711649A (en) 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
ES2527438T3 (es) 2006-08-08 2015-01-26 Metabolon, Inc. Marcadores de la hepatopatía grasa no alcohólica (NAFLD) y de la esteatohepatitis no alcohólica (NASH) y métodos de uso de los mismos
JP5101894B2 (ja) 2007-01-15 2012-12-19 サントリーホールディングス株式会社 高度不飽和脂肪酸及びこれを含有する脂質の製造方法
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2009154230A1 (ja) 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防/改善・治療薬
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
GB0907601D0 (en) 2009-05-01 2009-06-10 Equateq Ltd Novel methods
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
CN104010637A (zh) 2011-10-19 2014-08-27 尊贵科学有限公司 含有双同-γ-次亚麻油酸及/或15-羟基二十碳三烯酸的药物组合物及其使用方法
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
BR112014013098A2 (pt) 2011-11-29 2017-06-13 Dignity Sciences Ltd composições compreendendo ácidos graxos que têm 20 carbonos e métodos de produção e uso dos mesmos
KR102153143B1 (ko) 2012-01-06 2020-09-08 옴테라 파마슈티칼스, 인크. 유리 산 형태의 오메가-3 다중불포화 지방산의 dpa-농축 조성물
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
EP2833740B1 (en) 2012-04-04 2016-09-14 Pronova BioPharma Norge AS Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
CN110478342A (zh) 2012-05-10 2019-11-22 索卢泰克斯Na有限责任公司 含有天然专门促消退介质及其前体的具有抗炎活性的油
WO2014022816A2 (en) 2012-08-03 2014-02-06 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hetre and methods of treating or preventing arthritis using same
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
AU2015204531B2 (en) 2014-01-10 2019-11-14 Afimmune Limited Pharmaceutical compositions comprising 15-HEPE and methods of treating asthma and lung disorders using same
KR102391827B1 (ko) 2014-06-04 2022-04-27 디에스 바이오파마 리미티드 Dgla를 포함하는 약제학적 조성물 및 그의 용도
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
AU2016370626B2 (en) 2015-12-18 2020-08-20 Afimmune Limited Compositions comprising 15-HEPE and methods of using the same
WO2017118911A1 (en) 2016-01-07 2017-07-13 Dignity Sciences Limited Pharmaceutical compositions comprising dgla and use of same

Similar Documents

Publication Publication Date Title
JP2021073194A5 (ja)
JP2689991B2 (ja) 組成物
JP5558113B2 (ja) 生理冷却剤を含む組成物
EP3322488B1 (en) Cosmetic composition
JP2019189650A5 (ja)
JP2017526738A5 (ja)
JP2008543854A (ja) 炎症状態を治療するための組成物および方法
JP6682872B2 (ja) 口腔用シリカ分散安定化剤およびこれを含有する歯磨剤組成物
JP2008528644A5 (ja)
WO2007102243A1 (ja) 外用の医薬組成物
JP2015531344A5 (ja)
JP2015508068A5 (ja)
JP2013513612A5 (ja)
JP2023016959A (ja) 眼科用組成物
JP2017222722A5 (ja)
JP2016532654A5 (ja)
JP2007530498A5 (ja)
JP2011503167A5 (ja)
TW201703759A (zh) 調味劑及含有該調味劑的口腔用組合物
RU2006137282A (ru) Химически устойчивые композиции 4-гидрокси-тамоксифена
JP2023041793A5 (ja)
JP2015504860A5 (ja)
HRP20161594T1 (hr) Pripravci za liječenje rozaceje koji sadrže kitozan i amid dikarboksilne kiseline
JP6598744B2 (ja) 歯磨き剤組成物
JP2003342131A (ja) 頭皮治療剤組成物